DA
RVNC

Duality Advisers’s Revance Therapeutics, Inc. RVNC Stock Holding History

Duality Advisers’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-32,313
Closed -$527K – 862
2021
Q4 		$527K Buy
+32,313
New +$539K 0.06% 393

Other funds holding RVNC

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Duality Advisers's RVNC Position: Q1 2022 in Review

Duality Advisers sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2022, closing a stake of 32,313 shares — an estimated $527K sold.

Duality Advisers first reported a position in RVNC in Q4 2021 and held it in 1 quarter. The position peaked at $527K in Q4 2021. 156 funds tracked by Wall St. Rank hold RVNC as of Q1 2022.

  • Duality Advisers reported no remaining Revance Therapeutics, Inc. position as of Q1 2022 after selling out during the quarter.
  • Duality Advisers sold 32,313 Revance Therapeutics, Inc. shares in Q1 2022, an estimated $527K.
  • Duality Advisers first reported a position in Revance Therapeutics, Inc. in Q4 2021 and held it in 1 quarter.
  • Duality Advisers's Revance Therapeutics, Inc. position peaked at $527K in Q4 2021.
  • 156 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2022.

Based on Duality Advisers's 13F filing for Q1 2022, filed 9 May 2022.